{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:22:41Z","timestamp":1793384561840,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gallbladder carcinoma (GBC) is the most common malignant tumour in the biliary tract, but effective therapeutics are lacking. Based on our previous studies, miR-135a is a potential tool to inhibit GBC proliferation. In this study, we constructed miR-135a-loaded DSPE-PEG2000 liposomes modified with Anti-EGFR antibodies (Anti-EGFR-CIL-miR-135a). The results of an analysis of their physicochemical properties indicated the particle size of it was 222.0\u2009\u00b1\u20092.1\u2009nm in diameter with an uptake efficiency of 86.5%. Next, the post-treatment biological behaviours of GBC, specifically, invasion, metastasis and apoptosis, were evaluated. miR-135a inhibited GBC invasion and metastasis and promoted apoptosis compared to controls. Additionally, miR-135a targeted and regulated the expression of ROCK1, HOXA10 and BCL-2. Due to the targeted effects of Anti-EGFR-CIL-miR-135a, the GBC tumour growth rate was 60% lower in an <jats:italic>in vivo<\/jats:italic> xenograft-bearing mouse model compared to controls. Thus, Anti-EGFR-CIL-miR-135a is a promising therapeutic strategy to combat GBC.<\/jats:p>","DOI":"10.1038\/s41598-017-06234-8","type":"journal-article","created":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T09:39:13Z","timestamp":1500025153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Therapeutic effects of long-circulating miR-135a-containing cationic immunoliposomes against gallbladder carcinoma"],"prefix":"10.1038","volume":"7","author":[{"given":"Guanghua","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baobing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,20]]},"reference":[{"key":"6234_CR1","first-page":"99","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal, R. & Shaffer, E. A. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol \n                           6, 99 (2014).","journal-title":"Clin Epidemiol"},{"key":"6234_CR2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1245\/s10434-006-9224-4","volume":"14","author":"RP Kiran","year":"2007","unstructured":"Kiran, R. P., Pokala, N. & Dudrick, S. J. Incidence pattern and survival for gallbladder cancer over three decades\u2013an analysis of 10301 patients. Ann Surg Oncol \n                           14, 827 (2007).","journal-title":"Ann Surg Oncol"},{"key":"6234_CR3","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/35002607","volume":"403","author":"BJ Reinhart","year":"2000","unstructured":"Reinhart, B. J. et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature \n                           403, 901 (2000).","journal-title":"Nature"},{"key":"6234_CR4","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1126\/science.1065329","volume":"294","author":"RC Lee","year":"2001","unstructured":"Lee, R. C. & Ambros, V. An extensive class of small RNAs in Caenorhabditis elegans. Science \n                           294, 862 (2001).","journal-title":"Science"},{"key":"6234_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrd3179","volume":"9","author":"R Garzon","year":"2010","unstructured":"Garzon, R., Marcucci, G. & Croce, C. M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov \n                           9, 775 (2010).","journal-title":"Nat Rev Drug Discov"},{"key":"6234_CR6","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3748\/wjg.v22.i5.1787","volume":"22","author":"V Chandra","year":"2016","unstructured":"Chandra, V., Kim, J. J., Mittal, B. & Rai, R. MicroRNA aberrations: An emerging field for gallbladder cancer management. World J Gastroenterol \n                           22, 1787 (2016).","journal-title":"World J Gastroenterol"},{"key":"6234_CR7","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.1158\/0008-5472.CAN-12-2001","volume":"72","author":"AL Kasinski","year":"2012","unstructured":"Kasinski, A. L. & Slack, F. J. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res \n                           72, 5576 (2012).","journal-title":"Cancer Res"},{"key":"6234_CR8","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1038\/cddis.2012.134","volume":"3","author":"J Lin","year":"2012","unstructured":"Lin, J., Teo, S., Lam, D. H., Jeyaseelan, K. & Wang, S. MicroRNA-10b pleiotropically regulates invasion, angiogenicity and apoptosis of tumor cells resembling mesenchymal subtype of glioblastoma multiforme. Cell Death Dis \n                           3, e398 (2012).","journal-title":"Cell Death Dis"},{"key":"6234_CR9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1089\/hum.2008.134","volume":"20","author":"J Torrisani","year":"2009","unstructured":"Torrisani, J. et al. let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther \n                           20, 831 (2009).","journal-title":"Hum Gene Ther"},{"key":"6234_CR10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/cas.12463","volume":"105","author":"H Zhou","year":"2014","unstructured":"Zhou, H. et al. MicroRNA-135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer. Cancer Sci \n                           105, 956 (2014).","journal-title":"Cancer Sci"},{"key":"6234_CR11","first-page":"262","volume":"22","author":"Y Zhou","year":"2003","unstructured":"Zhou, Y. Significance of Expression of Epidermal Growth Factor (EGF) and Its Receptor (EGFR) in Chronic Cholecystitis and Gallbladder Carcinoma. Cancer-Am Cancer Soc \n                           22, 262 (2003).","journal-title":"Cancer-Am Cancer Soc"},{"key":"6234_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.7150\/ijms.5.285","volume":"5","author":"M Kaufman","year":"2008","unstructured":"Kaufman, M. et al. EGFR expression in gallbladder carcinoma in North America. Int J Med Sci \n                           5, 285 (2008).","journal-title":"Int J Med Sci"},{"key":"6234_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1590\/S0102-67202014000200009","volume":"27","author":"SR Pais-Costa","year":"2014","unstructured":"Pais-Costa, S. R., Farah, J. F., Artigiani-Neto, R., Martins, S. J. & Goldenberg, A. Evaluation of P53, E-cadherin, Cox-2, and EGFR protein imunnoexpression on prognostic of resected gallbladder carcinoma. Arq Bras Cir Dig \n                           27, 126 (2014).","journal-title":"Arq Bras Cir Dig"},{"key":"6234_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/B978-0-12-416039-2.00007-0","volume":"502","author":"DB Kirpotin","year":"2012","unstructured":"Kirpotin, D. B. et al. Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzymol \n                           502, 139 (2012).","journal-title":"Methods Enzymol"},{"key":"6234_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/0005-2736(94)00263-O","volume":"1234","author":"K Maruyama","year":"1995","unstructured":"Maruyama, K. et al. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta \n                           1234, 74 (1995).","journal-title":"Biochim Biophys Acta"},{"key":"6234_CR16","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.2147\/IJN.S117618","volume":"11","author":"V Juang","year":"2016","unstructured":"Juang, V., Lee, H. P., Lin, A. M. & Lo, Y. L. Cationic PEGylated liposomes incorporating an antimicrobial peptide tilapia hepcidin 2-3: an adjuvant of epirubicin to overcome multidrug resistance in cervical cancer cells. Int J Nanomedicine \n                           11, 6047 (2016).","journal-title":"Int J Nanomedicine"},{"key":"6234_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/cas.12072","volume":"104","author":"Y Yamada","year":"2013","unstructured":"Yamada, Y. et al. Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma. Cancer Sci \n                           104, 304 (2013).","journal-title":"Cancer Sci"},{"key":"6234_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.7150\/ijbs.8097","volume":"10","author":"Z Dang","year":"2014","unstructured":"Dang, Z. et al. MicroRNA-135a Inhibits Cell Proliferation by Targeting Bmi1 in Pancreatic Ductal Adenocarcinoma. Int J Biol Sci \n                           10, 733 (2014).","journal-title":"Int J Biol Sci"},{"key":"6234_CR19","doi-asserted-by":"publisher","first-page":"e85205","DOI":"10.1371\/journal.pone.0085205","volume":"9","author":"JY Shin","year":"2014","unstructured":"Shin, J. Y. et al. MicroRNA 135a suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer. Plos One \n                           9, e85205 (2014).","journal-title":"Plos One"},{"key":"6234_CR20","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1182\/blood-2009-02-204842","volume":"114","author":"A Navarro","year":"2009","unstructured":"Navarro, A. et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood \n                           114, 2945 (2009).","journal-title":"Blood"},{"key":"6234_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccr.2013.06.006","volume":"24","author":"LA Martin","year":"2013","unstructured":"Martin, L. A. & Dowsett, M. BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer? Cancer Cell \n                           24, 7 (2013).","journal-title":"Cancer Cell"},{"key":"6234_CR22","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s10495-012-0777-3","volume":"17","author":"JJ Steinle","year":"2012","unstructured":"Steinle, J. J. Retinal endothelial cell apoptosis. Apoptosis \n                           17, 1258 (2012).","journal-title":"Apoptosis"},{"key":"6234_CR23","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1038\/onc.2014.222","volume":"34","author":"A Kroiss","year":"2015","unstructured":"Kroiss, A. et al. Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene \n                           34, 2846 (2015).","journal-title":"Oncogene"},{"key":"6234_CR24","first-page":"364","volume":"48","author":"WW Tang","year":"2013","unstructured":"Tang, W. W., Wan, G. P., Wan, Y. C., Zhang, L. & Cheng, W. J. [Effects of miR-135a on HOXA10 expression, proliferation and apoptosis of ovarian cancer cells]. Zhonghua Fu Chan Ke Za Zhi \n                           48, 364 (2013).","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"6234_CR25","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.cellsig.2014.03.002","volume":"26","author":"W Tang","year":"2014","unstructured":"Tang, W. et al. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression. Cell Signal \n                           26, 1420 (2014).","journal-title":"Cell Signal"},{"key":"6234_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.bbrc.2014.09.025","volume":"452","author":"J Zhao","year":"2014","unstructured":"Zhao, J. et al. miR-135a inhibition protects A549 cells from LPS-induced apoptosis by targeting Bcl-2. Biochem Biophys Res Commun \n                           452, 951 (2014).","journal-title":"Biochem Biophys Res Commun"},{"key":"6234_CR27","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/crj.12091","volume":"9","author":"M Ramamoorth","year":"2015","unstructured":"Ramamoorth, M. & Narvekar, A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res \n                           9, E1 (2015).","journal-title":"J Clin Diagn Res"},{"key":"6234_CR28","first-page":"467","volume":"9","author":"V Sanna","year":"2014","unstructured":"Sanna, V., Pala, N. & Sechi, M. Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine \n                           9, 467 (2014).","journal-title":"Int J Nanomedicine"},{"key":"6234_CR29","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1038\/sj.gt.3302877","volume":"13","author":"K Foster","year":"2006","unstructured":"Foster, K., Foster, H. & Dickson, J. G. Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther \n                           13, 1677 (2006).","journal-title":"Gene Ther"},{"key":"6234_CR30","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1016\/j.biomaterials.2008.04.036","volume":"29","author":"M Morille","year":"2008","unstructured":"Morille, M., Passirani, C., Vonarbourg, A., Clavreul, A. & Benoit, J. P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials \n                           29, 3477 (2008).","journal-title":"Biomaterials"},{"key":"6234_CR31","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1172\/JCI33494","volume":"117","author":"S Akhtar","year":"2007","unstructured":"Akhtar, S. & Benter, I. F. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest \n                           117, 3623 (2007).","journal-title":"J Clin Invest"},{"key":"6234_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrd2310","volume":"6","author":"A de Fougerolles","year":"2007","unstructured":"de Fougerolles, A., Vornlocher, H. P., Maraganore, J. & Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov \n                           6, 443 (2007).","journal-title":"Nat Rev Drug Discov"},{"key":"6234_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0005-2736(95)00138-S","volume":"1239","author":"CB Hansen","year":"1995","unstructured":"Hansen, C. B., Kao, G. Y., Moase, E. H., Zalipsky, S. & Allen, T. M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta \n                           1239, 133 (1995).","journal-title":"Biochim Biophys Acta"},{"key":"6234_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/wnan.66","volume":"2","author":"PP Adiseshaiah","year":"2010","unstructured":"Adiseshaiah, P. P., Hall, J. B. & McNeil, S. E. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol \n                           2, 99 (2010).","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"6234_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-800148-6.00001-8","volume":"88","author":"T Goodwin","year":"2014","unstructured":"Goodwin, T. & Huang, L. Nonviral vectors: we have come a long way. Adv Genet \n                           88, 1 (2014).","journal-title":"Adv Genet"},{"key":"6234_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1021\/nn800551s","volume":"3","author":"AA Bhirde","year":"2009","unstructured":"Bhirde, A. A. et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. Acs Nano \n                           3, 307 (2009).","journal-title":"Acs Nano"},{"key":"6234_CR37","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1021\/nl102184c","volume":"10","author":"J Shi","year":"2010","unstructured":"Shi, J., Votruba, A. R., Farokhzad, O. C. & Langer, R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett \n                           10, 3223 (2010).","journal-title":"Nano Lett"},{"key":"6234_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0169-409X(00)00133-2","volume":"46","author":"CW Pouton","year":"2001","unstructured":"Pouton, C. W. & Seymour, L. W. Key issues in non-viral gene delivery. Adv Drug Deliv Rev \n                           46, 187 (2001).","journal-title":"Adv Drug Deliv Rev"},{"key":"6234_CR39","doi-asserted-by":"crossref","unstructured":"Mortensen, J. H. et al. Targeted Antiepidermal Growth Factor Receptor (Cetuximab) Immunoliposomes Enhance Cellular Uptake In Vitro and Exhibit Increased Accumulation in an Intracranial Model of Glioblastoma Multiforme. J Drug Deliv \n                           2013 (2013).","DOI":"10.1155\/2013\/209205"},{"key":"6234_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10549-008-0043-0","volume":"115","author":"J Gao","year":"2009","unstructured":"Gao, J. et al. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity. Breast Cancer Res Treat \n                           115, 29 (2009).","journal-title":"Breast Cancer Res Treat"},{"key":"6234_CR41","first-page":"1172","volume":"8","author":"JW Park","year":"2002","unstructured":"Park, J. W. et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res \n                           8, 1172 (2002).","journal-title":"Clin Cancer Res"},{"key":"6234_CR42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijpharm.2015.02.034","volume":"484","author":"A Wicki","year":"2015","unstructured":"Wicki, A. et al. Large-scale manufacturing of GMP-compliant Anti-EGFR targeted nanocarriers: Production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial. Int J Pharm \n                           484, 8 (2015).","journal-title":"Int J Pharm"},{"key":"6234_CR43","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ijpharm.2015.01.016","volume":"479","author":"YD Limasale","year":"2015","unstructured":"Limasale, Y. D., Tezcaner, A., Ozen, C., Keskin, D. & Banerjee, S. Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells. Int J Pharm \n                           479, 364 (2015).","journal-title":"Int J Pharm"},{"key":"6234_CR44","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1158\/1078-0432.CCR-14-1194","volume":"21","author":"B Liang","year":"2015","unstructured":"Liang, B. et al. Integrinbeta6-targeted immunoliposomes mediate tumor-specific drug delivery and enhance therapeutic efficacy in colon carcinoma. Clin Cancer Res \n                           21, 1183 (2015).","journal-title":"Clin Cancer Res"},{"key":"6234_CR45","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1021\/ar200054n","volume":"44","author":"J Shi","year":"2011","unstructured":"Shi, J., Xiao, Z., Kamaly, N. & Farokhzad, O. C. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res \n                           44, 1123 (2011).","journal-title":"Acc Chem Res"},{"key":"6234_CR46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0163-7827(03)00032-8","volume":"42","author":"P Sapra","year":"2003","unstructured":"Sapra, P. & Allen, T. M. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res \n                           42, 439 (2003).","journal-title":"Prog Lipid Res"},{"key":"6234_CR47","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1039\/c2cs15327k","volume":"41","author":"M Elsabahy","year":"2012","unstructured":"Elsabahy, M. & Wooley, K. L. Design of polymeric nanoparticles for biomedical delivery applications**. Chem Soc Rev \n                           41, 2545 (2012).","journal-title":"Chem Soc Rev"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-06234-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-06234-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-06234-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T07:07:29Z","timestamp":1671779249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-06234-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,20]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["6234"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-06234-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,20]]},"assertion":[{"value":"28 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5982"}}